Source comparison
MK-677 Mechanism: Ghrelin Receptor Activation vs Exogenous GH
MK-677 binds selectively to the growth hormone secretagogue receptor type 1a (GHSR1a). The same receptor activated by ghrelin, the 'hunger hormone' released by stomach cells when energy stores are depleted. This binding triggers a signaling cascade in the arcu
This comparison does not assign a generated winner or score.
- MK-677 binds selectively to the growth hormone secretagogue receptor type 1a (GHSR1a). The same receptor activated by ghrelin, the 'hunger hormone' released by stomach cells when energy stores are depleted. This binding triggers a signaling cascade in the arcuate nucleus of the hypothalamus that stimulates growth hormone-releasing hormone (GHRH) secretion, which in turn prompts pulsatile GH release from anterior pituitary somatotrophs. The result is endogenous GH secretion that follows the body's natural pulsatile pattern. Distinct from the pharmacokinetic profile of injected recombinant GH.
- Clinical data from a 2-year randomised trial published in the Journal of Clinical Endocrinology & Metabolism showed MK-677 at 25mg daily produced mean serum IGF-1 increases of 72.9% above baseline by week 2, sustained throughout the study period without tachyphylaxis. Importantly, endogenous GH secretion patterns remained intact. Subjects maintained physiological pulse frequency (6–8 pulses per 24 hours) rather than the suppressed pulsatility seen with exogenous GH administration. This preservation of natural rhythm matters for downstream metabolic effects that depend on pulse amplitude rather than steady-state hormone levels.
- The ghrelin mimetic action creates predictable side effects. Increased appetite occurs in roughly 65% of subjects at therapeutic doses because GHSR1a activation directly stimulates neuropeptide Y and agouti-related peptide pathways in the hypothalamus. The same circuits that drive hunger during caloric deficit. Transient insulin resistance and mild fasting glucose elevation (5–8 mg/dL above baseline) appear in approximately 30% of subjects due to GH-mediated lipolysis and increased free fatty acid availability, which competes with glucose uptake in peripheral tissues. Our team has found these effects normalize within 4–6 weeks in most research models.